The FDA on November 16, 2017, approved SUTENT® for the adjuvant treatment of adult patients at high risk of recurrent Renal Cell Carcinoma, following nephrectomy. SUTENT® is a product of Pfizer Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
